Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

The development of bispecific antibodies has attracted substantial interest, and many different formats have been described. Those specifically containing an Fc part are mostly tetravalent, such as stabilized IgG-scFv fusions or dual-variable domain (DVD) IgGs. However, although they exhibit IgG-like properties and technical developability, these formats differ in size and geometry from classical IgG antibodies. Thus, considerable efforts focus on bispecific heterodimeric IgG antibodies that more closely mimic natural IgG molecules. The inherent chain association problem encountered when producing bispecific heterodimeric IgG antibodies can be overcome by several methods. While technologies like knobs-into-holes (KiH) combined with a common light chain or the CrossMab technology enforce the correct chain association, other approaches, e.g., the dual-acting Fab (DAF) IgGs, do not rely on a heterodimeric Fc part. This review discusses the state of the art in bispecific heterodimeric IgG antibodies, with an emphasis on recent progress.

[1]  Pavel Strop,et al.  Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. , 2012, Journal of molecular biology.

[2]  Ulrik B. Nielsen,et al.  Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.

[3]  M. Nussenzweig,et al.  Enhanced HIV-1 neutralization by antibody heteroligation , 2012, Proceedings of the National Academy of Sciences.

[4]  R. Salgia,et al.  Role of MetMAb (OA-5D5) in c-MET active lung malignancies , 2011, Expert opinion on biological therapy.

[5]  G. A. Lazar,et al.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens , 2011, mAbs.

[6]  F. Gueneau,et al.  Dual Specificity of Anti-CXCL10-CXCL9 Antibodies Is Governed by Structural Mimicry* , 2011, The Journal of Biological Chemistry.

[7]  D. Holmes.  Buy buy bispecific antibodies , 2011, Nature Reviews Drug Discovery.

[8]  M. Sliwkowski,et al.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.

[9]  C. Klein,et al.  A Human Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis , 2011, Microcirculation.

[10]  C. Jakob,et al.  Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design , 2011, mAbs.

[11]  Chris Cain.  Crossing over to bispecificity , 2011 .

[12]  A. Heath,et al.  A Novel Redox Method for Rapid Production of Functional Bi-Specific Antibodies For Use in Early Pilot Studies , 2011, PloS one.

[13]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Guy Georges,et al.  Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.

[15]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[16]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[17]  P. Carter,et al.  Introduction to current and future protein therapeutics: a protein engineering perspective. , 2011, Experimental cell research.

[18]  U. Brinkmann,et al.  Bispecific digoxigenin-binding antibodies for targeted payload delivery , 2011, Proceedings of the National Academy of Sciences.

[19]  J. Fitzgerald,et al.  Rational engineering of antibody therapeutics targeting multiple oncogene pathways , 2011, mAbs.

[20]  M. Muda,et al.  Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. , 2011, Protein engineering, design & selection : PEDS.

[21]  R. Kelley,et al.  High Affinity Antigen Recognition of the Dual Specific Variants of Herceptin Is Entropy-Driven in Spite of Structural Plasticity , 2011, PloS one.

[22]  U. Brinkmann,et al.  Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains , 2011, Antimicrobial Agents and Chemotherapy.

[23]  Janet Do,et al.  Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth , 2011, Clinical Cancer Research.

[24]  R. Lerner,et al.  Chemical generation of bispecific antibodies , 2010, Proceedings of the National Academy of Sciences.

[25]  エリン エイチ． クリステンセン，,et al.  Coiled-coil and / or the tether containing protein complexes and use thereof , 2010 .

[26]  V. Buatois,et al.  Pan–CC Chemokine Neutralization Restricts Splenocyte Egress and Reduces Inflammation in a Model of Arthritis , 2010, The Journal of Immunology.

[27]  T. Igawa,et al.  VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. , 2010, Protein engineering, design & selection : PEDS.

[28]  L. Croner,et al.  Stability engineering of scFvs for the development of bispecific and multivalent antibodies. , 2010, Protein engineering, design & selection : PEDS.

[29]  Самьюэл Дэвис,et al.  Readily isolated bispecific antibodies with native immunoglobulin format , 2010 .

[30]  Lawren C. Wu,et al.  Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling* , 2010, The Journal of Biological Chemistry.

[31]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[32]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[33]  D. Chelius,et al.  Structural and functional characterization of the trifunctional antibody catumaxomab , 2010, mAbs.

[34]  M. Wittekind,et al.  Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.

[35]  G. Himmler,et al.  Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. , 2010, Protein engineering, design & selection : PEDS.

[36]  J. Huston,et al.  SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.

[37]  D. Seimetz,et al.  Catumaxomab , 2010, mAbs.

[38]  K. Stubenrauch,et al.  Impact of Molecular Processing in the Hinge Region of Therapeutic IgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys , 2010, Drug Metabolism and Disposition.

[39]  P. Parren,et al.  Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo , 2009, Nature Biotechnology.

[40]  F. Peale,et al.  Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.

[41]  Scott M Glaser,et al.  Antibody therapeutics, antibody engineering, and the merits of protein stability. , 2008, Current opinion in drug discovery & development.

[42]  H. Rammensee,et al.  Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. , 2008, Cancer research.

[43]  I. Kasman,et al.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.

[44]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[45]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[46]  N. Fischer,et al.  Bispecific Antibodies: Molecules That Enable Novel Therapeutic Strategies , 2007, Pathobiology.

[47]  M. Westphal,et al.  A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.

[48]  Margarida Saraiva,et al.  A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[49]  도모유키 이가와,et al.  Methods for producing polypeptides by regulating polypeptide association , 2006 .

[50]  P. Carter,et al.  Bispecific human IgG by design. , 2001, Journal of immunological methods.

[51]  B. Wollenberg,et al.  Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. , 1999, Journal of immunology.

[52]  Camellia W. Adams,et al.  An efficient route to human bispecific IgG , 1998, Nature Biotechnology.

[53]  J. Wells,et al.  Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. , 1997, Journal of molecular biology.

[54]  L. Presta,et al.  Remodeling domain interfaces to enhance heterodimer formation , 1997, Protein science : a publication of the Protein Society.

[55]  L. Presta,et al.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.

[56]  S. Thierfelder,et al.  Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.

[57]  V. Diehl,et al.  Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. , 1994, Science.

[58]  A. Plückthun,et al.  Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of Escherichia coli , 1993, Nature Biotechnology.

[59]  J. Tso,et al.  Formation of a bispecific antibody by the use of leucine zippers. , 1992, Journal of immunology.

[60]  W. de Lau,et al.  Absence of preferential homologous H/L chain association in hybrid hybridomas. , 1991, Journal of immunology.

[61]  S. Ménard,et al.  Hybrid Antibodies in Cancer Diagnosis and Therapy , 1989, The International journal of biological markers.

[62]  G. Fuh,et al.  Improving antibody binding affinity and specificity for therapeutic development. , 2009, Methods in molecular biology.

[63]  ANTIBODY MODIFICATION METHOD FOR PURIFYING BISPECIFIC ANTIBODY - European Patent Office - EP 2009101 A1 , 2008 .